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It has been proposed that PPAR-dependent, accelerated catabolism of proinflammatory mediators may contribute to the fast
resolution of inflammation. Because retinoid X receptors are obligate heterodimer partners of PPARs, we investigated the impact
of deleting hepatocyte-specific RXRα on the antiedema effect of PPAR agonists. In wild-type mice (WT), pretreatment with the
PPARα agonist perfluorooctanoic acid diminished carrageenan-induced paw edema by 66±10%. This effect was essentially absent
(13 ± 8%) in hepatocyte-specific RXRα-deficient mice. Similarly, pretreatment of WT mice with the PPARδ agonist L-783483 or
the PPARγ agonist L-805645 caused 54±1% and 38±8% reduction in carrageenan-induced paw edema, respectively. These effects
were also significantly diminished or absent in hepatocyte-specific RXRα-deficient mice. In contrast, aspirin reduced carrageenan-
induced paw edema equally in WT and hepatocyte-specific RXRα-deficient mice. The identification of RXRα as an important
factor involved in the antiedema effect produced by agonists of the three PPAR subtypes is a significant achievement towards the
goal of designing novel, effective anti-inflammatory drugs.
Copyright © 2006 Y.-J. Y. Wan and M. Z. Badr. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
It has been reported by us [1–3], as well as by others [4–6]
that agonists of the peroxisome proliferator-activated recep-
tors (PPARs) diminish inflammatory responses. In attempt-
ing to delineate mechanisms involved in this effect, it was
proposed among various other postulates that termination of
the biological activity of proinflammatory mediators might
occur in the liver via PPAR-dependent catabolic pathways
[4]. These pathways are known to be augmented following
exposure to PPAR agonists, particularly those which activate
PPARα [4].
Retinoid X receptor alpha (RXRα) is reported to play a
central role in mediating PPAR-induced effects [7–9], and
the expression of both PPARs and RXRs decreases in tissues,
including the liver of animal models of inflammation [10].
Therefore, we hypothesized that the absence of hepatocyte-
specific RXRα shall interfere with the ability of PPAR ago-
nists to control inflammation. Using the intraplantar injec-
tion of carrageenan as a well-established in vivo model of in-
flammation, the present experiments were designed to eval-
uate the anti-inflammatory effect of subtype-selective PPAR
ligands in hepatocyte-specific RXRα-deficient mice. Results
show that hepatocytic RXRα plays an important role in me-
diating the PPAR-induced amelioration of cutaneous inflam-
mation. We postulate that the hepatocyte-specific RXRα is
involved in enhancing the metabolic removal of proinflam-
matory mediators and/or increasing the production of anti-
inflammatory mediators in the liver.
The identification of a specific receptor subtype (RXRα)
in a specific cell population (hepatocytes) may prove instru-
mental in the pursuit to fully elucidate mechanisms involved
in the antiinflammatory effect of PPAR agonists, as well as
invaluable to the effort of developing novel effective anti-
inflammatory drugs.
MATERIALS AND METHODS
Animals and materials
Male hepatocyte-specific RXRα-deficient mice were pro-
duced as reported previously [9]. Animals were cared for in
accordance to the guidelines set forth by the National In-
stitutes of Health regarding the proper treatment and use
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Figure 1: Carrageenan-induced paw edema in hepatocyte-specific
RXRα-deficient mice. Wild-type and hepatocyte-specific RXRα-
deficient mice were treated with 30 μL of 1% carrageenan in nor-
mal saline subcutaneously into the midplantar region of the right
hindpaw. Carrageenan-induced edema, reflected as an increase in
dorsal-to-ventral paw thickness, was measured with a microcaliper.
Values represent mean ±SEM. n = 8 mice per group.
of laboratory animals. All experiments were approved by
the University of Missouri–Kansas City Institutional Animal
Care and Use Committee.
Carrageenan (type IV, lambda) was obtained from Fluka
(Milwaukee, WI), while aspirin and perfluorooctanoic acid
were from Sigma Aldrich (St Louis, MO). The PPARγ ago-
nist L-805645 and PPARδ agonist L-738483 were provided
by Merck (Rahway, NJ).
Animal treatment
Tested compounds (200 μL in normal saline at a dose of
100mg/kg), or the saline vehicle, was administered in-
traperitoneally to wild-type and hepatocyte-specific RXRα-
deficient mice. Since we previously observed that PPAR ago-
nists equally diminished inflammation when given 30 min-
utes prior to, or 90 minutes after the induction of paw edema
[1], we limited the present study to the 30 minute pre-
carrageenan injection of PPAR agonists. Carrageenan (30 μL
of 1% in normal saline), or an equivalent volume of saline,
was subcutaneously injected into the midplantar region of
the right hindpaw. Carrageenan-induced edema, reflected as
an increase in dorsal-to-ventral paw thickness, was measured
with a microcaliper (Mitutoyo Corp; Kanagawa, Japan). The
average of 3measurements at each time-point was calculated.
Data analysis and statistics
Carrageenan-evoked edema responses were analyzed by Stu-
dent’s t test (Figures 1 and 6), or ANOVA (Figures 2–5).
P < .05 was considered significant.
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Figure 2: Effect of the PPARα agonist perfluorooctanoic acid (PFOA)
on the temporal profile of carrageenan-induced paw edema in wild-
type and hepatocyte-specific RXRα-deficient mice. Wild-type (A) and
hepatocyte-specific RXRα-deficient mice (B) were treated intraperi-
toneally with (100mg/kg) of PFOA, 30 minutes before induction
of inflammation. As indicated by the arrow, carrageenan (1%, in-
traplantar) was injected at t = 0. Carrageenan-induced edema is
reflected by an increase in paw thickness. Values represent mean
±SEM. n = 4 mice per group. ∗P < .05 versus corresponding wild-
type point.
RESULTS
Influence of hepatocyte-specific RXRα on
carrageenan-induced paw edema
As illustrated in Figure 1, intraplantar injection of car-
rageenan in wild-type mice increased paw thickness, with
a peak at approximately 1 hr post-injection. The maximal
Y.-J. Y. Wan and M. Z. Badr 3
−1 0 1 2 3 4
Time (h)
Carrageenan
L-783483
1
2
3
4
Pa
w
th
ic
kn
es
s
(m
m
)
Control
L-783483
∗ ∗ ∗
(a)
−1 0 1 2 3 4
Time (h)
Carrageenan
L-783483
1
2
3
4
Pa
w
th
ic
kn
es
s
(m
m
)
Control
L-783483
(b)
Figure 3: Antiedema effect of the PPARδ agonist L-738483 on carrageenan-induced paw edema in wild-type and hepatocyte-specific RXRα-
deficient mice. Wild-type (a) and hepatocyte-specific RXRα-deficient mice (b) were treated intraperitoneally with (100mg/kg) of L-738484,
30 minutes before induction of inflammation. As indicated by the arrow, carrageenan (1%, intraplantar) was injected at t = 0. Carrageenan-
induced edema is reflected by an increase in paw thickness. Values represent mean ±SEM. n = 3–5 mice per group. ∗P < .05 versus
corresponding wild-type point.
increase in paw thickness was 35% over basal values, and
lasted through the 4 hr duration of the experiment. Mice
lacking hepatocyte-specific RXRα also showed a comparable
increase and trend in paw thickness in response to intraplan-
tar carrageenan injection (Figure 1).
Antiedema effect of PPAR agonists in
hepatocyte-specific RXRα-deficient mice
In wild-type mice, pretreatment with 100mg/kg of the
PPARα agonist perfluorooctanoic acid (PFOA) diminished
carrageenan-induced paw edema by 66 ± 10% 2–4 h fol-
lowing carrageenan injection (Figures 2(a) and 6). This ef-
fect was essentially absent (13 ± 8%) in hepatocyte-specific
RXRα-deficient mice (Figures 2(b) and 6). Similarly, pre-
treatment of wild-type mice with similar doses of either of
the PPARδ agonist L-783483, or the PPARγ agonist L-805645
caused 54 ± 1% and 38 ± 8% reduction in carrageenan-
induced paw edema, respectively (Figures 3(a), 4(a), and 6).
These effects were significantly lower (30 ± 6%) or absent
(8±5%) in hepatocyte-specific RXRα deficient mice, respec-
tively (Figures 3(b), 4(b), and 6). Conversely, aspirin which
is a known inhibitor of the cyclooxygenase enzyme, reduced
carrageenan-induced paw edema equally in wild-type and
hepatocyte-specific RXRα-deficient mice (Figures 5 and 6).
The reduction in paw edema was 51± 12% and 51± 3% x in
these two groups of mice, respectively (Figure 6).
DISCUSSION
Retinoid X receptors (RXR) play a central role as obli-
gate heterodimer partners for numerous nuclear receptors,
including PPARs [7]; thereby serving as master regulators
of crucial pathways [7]. The RXR/PPAR heterodimer is ac-
tivated by agonists of either RXR or PPAR, leading to the
activation of specific pathways [8], with the combination of
RXR and PPAR agonists causing a greater effect than agonists
of either receptor alone [8]. Genetic deletion of hepatocyte-
specific RXRα drastically, albeit not completely, interfered
with PPAR-mediated pathways [9, 10]. In light of these facts,
this study was pursued to take advantage of the availability
of mice lacking hepatocyte RXRα to investigate potential role
played by the liver in the antiedema effect ascribed to PPAR
agonists.
Our data clearly show that the absence of hepatocyte-
specific RXRα significantly diminished the ability of ago-
nists of PPARα, PPARδ, and PPARγ to exert antiedema ef-
fect in vivo, while exhibiting no effect on aspirin-induced
antiedema (Figures 2–6). A previous study concluded that
activation of PPARα hastened the catabolic termination of
the inflammatory response to leukotriene B4 [4]. In support
of this conclusion, preliminary experiments by the same au-
thors showed diminished plasma clearance of leukotriene B4
in PPARα-deficient mice, as compared to wild-type mice [4].
It should be noted however that in contrast to the beneficial
effect of PPARα agonists in controlling inflammatory pro-
cesses, published reports present evidence for a proinflam-
matory response to these agonists; an effect that is explained
by potential differences in cell- and/or tissue-specific suscep-
tibility [11].
PPARγ agonists have been shown to interfere with nu-
merous pathways involved in the inflammatory process, in
the course of exerting their reported anti-inflammatory ac-
tivity [11]. However, whether agonists of PPARγ and/or
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Figure 4: Effect of the PPARγ agonist L-805645 on the profile of
carrageenan-induced paw edema in wild-type and hepatocyte-specific
RXRα-deficient mice. Wild-type (a) and hepatocyte-specific RXRα-
deficient mice (b) were treated intraperitoneally with (100mg/kg)
of L-805645, 30 minutes before induction of inflammation. As in-
dicated by the arrow, carrageenan (1%, intraplantar) was injected
at t = 0. Carrageenan-induced edema is reflected by an increase
in paw thickness. Values represent mean ±SEM. n = 4–6 mice per
group. ∗P < .05 versus corresponding wild-type point.
PPARδ recruit the hepatic metabolic machinery to control
inflammation is not reported in the literature. Thus, this
is the first report, to our knowledge, that presents an ev-
idence for a unifying mechanism involving the liver, ex-
plaining the anti-inflammatory effect of agonists of the three
known PPAR subtypes.
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Figure 5: Effect of aspirin on carrageenan-induced paw edema in
wild-type and hepatocyte-specific RXRα-deficient mice.Wild-type (a)
and hepatocyte-specific RXRα-deficient mice (b) were treated in-
traperitoneally with (50mg/kg) of aspirin, 30minutes before induc-
tion of inflammation. As indicated by the arrow, carrageenan (1%,
intraplantar) was injected at t = 0. Carrageenan-induced edema
is reflected by an increase in paw thickness. Values represent mean
±SEM. n = 3–5 mice per group. ∗P < .05 versus corresponding
wild-type point.
The specific requirement for RXRα by all PPAR sub-
types, observed in this study, may be explained by the fact
that this receptor is a heterodimer partner of the three PPAR
subtypes. The absence of RXRα is consequently expected to
hinder the activation of pathways controlled by agonists se-
lective to any of the various PPAR subtypes. In order to
Y.-J. Y. Wan and M. Z. Badr 5
PFOA
PPARα
L-805645
PPARγ
L-783483
PPARδ
Aspirin
COX
0
25
50
75
100
A
n
ti
ed
em
a
eff
ec
t
(%
co
n
tr
ol
,2
-4
h
rs
)
(a)
PFOA
PPARα
L-805645
PPARγ
L-783483
PPARδ
Aspirin
COX
0
25
50
75
100
A
n
ti
ed
em
a
eff
ec
t
(%
co
n
tr
ol
,2
-4
h
rs
)
∗
∗
∗
(b)
Figure 6: Percent inhibition of paw edema by various PPAR agonists
and aspirin in wild-type (a) and hepatocyte-specific RXRα-deficient
(b) mice. Data shown in Figures 2–5 above are expressed as the per-
centage change in paw edema relative to control group 2–4 h after
carrageean injection. Values represent mean ±SEM. N = 3–6 mice
per group. ∗P < .05 versus corresponding wild-type group.
explain the residual anti-inflammatory effect of PPAR ago-
nists observed in hepatocyte-specific RXRα-deficient mice,
we propose the following. (1) It is noteworthy that these
agonists have been shown to produce effects that are not
PPAR-dependent [12–16]. This is an unlikely explanation
however in light of the fact that preliminary experiments in
our laboratories reveal that PPARα plays a significant role in
mediating the anti-inflammatory effect of its agonists (not
shown). (2) Another possibility that may explain the resid-
ual anti-inflammatory effect of PPAR agonists observed in
hepatocyte-specific RXRα-deficient mice takes into consid-
erations the fact that these mice retain the ability to express
RXRβ and RXRγ in hepatocytes [9, 10]. Both of these recep-
tor subtypes may act as heterodimer partners of PPARs in the
absence of RXRα [9, 10]. (3) Since our animal model lacks
RXRα exclusively in hepatocytes [10], RXRα present in liver
cell types other than hepatocytes may contribute to the par-
tial anti-inflammatory effect of PPAR agonists observed in
these mice. (4) Lastly, whether there are PPAR-mediated ef-
fects that are not fully dependent on the heterodimerization
of these receptors with RXRs is an interesting postulate that
deserves evaluation.
In conclusion, data presented here show that hepatic
events involving RXRα are crucial to the antiedema effect
of PPAR agonists. These effects may include acceleration of
the metabolic removal of proinflammatory mediators and/or
enhanced production of antiinflammatory mediators in the
liver. Identifying hepatocyte-specific RXRα as a crucial link
in the mechanism by which PPAR agonists produce anti-
inflammatory effect is indeed a significant first step to-
wards fully defining molecular events involved in this ac-
tion, as well as designing novel, effective anti-inflammatory
drugs.
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